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CCR5Efforts to address HIV infection have been highly successful, enabling chronic suppression of viral repli-
cation with once-daily regimens. More recent research into HCV therapeutics have also resulted in very
promising clinical candidates. This Digest explores similarities and differences in the two ﬁelds and com-
pares the chronology of drug discovery relative to the availability of enabling tools, and concludes that
safe and convenient, once-daily regimens are likely to reach approval much more rapidly for HCV than
was the case for HIV.
 2013 Elsevier Ltd. Open access under CC BY-NC-ND license.The discovery of drugs for the effective treatment of human
immunodeﬁciency virus (HIV) infection has been a prominent area
of success for the pharmaceutical industry, with dramatic beneﬁts
for human health worldwide. Twenty-seven small molecules have
been approved since research in the area began in the 1980s.1 At
the same time, much progress has been made in the general opti-
mization of molecular properties for convenient oral regimens.
More recently, the race has been on to ﬁnd small molecules to ad-
dress chronic infection with hepatitis C virus (HCV). Great progress
has been made: treatment paradigms are being revolutionized
with the advent of direct-acting antivirals. This article was born
out of a desire to explore to what extent medicinal chemistry as
applied in the discovery of HCV has beneﬁtted from earlier experi-
ences with HIV.
Basis of comparison. In order to compare the histories of drug
discovery for HIV and HCV, we chose to track the chronology of
major events along with the availability of enabling research tools.
Screening for suppression of viral replication in cells was a funda-
mental assay for lead optimization which for HCV came (in theform of the sub-genomic replicon)2 a full 10 years after the discov-
ery of the virus, delaying the development of the ﬁeld considerably.
We therefore also compared the chronologies relative to the avail-
ability of this tool. For some classes, the year of entry into clinical
development is estimated. For both HIV and HCV, effective sup-
pression of the virus in patients requires combination therapy for
maximal compliance, and for this reason we have concentrated
our analysis on oral agents. For HCV, we project probable approval
dates based upon current Phase 3 trials. While different strains of
the viruses cause signiﬁcant morbidity in different geographic re-
gions, we compare here the results of the main focus of discovery
efforts thus far: HIV-1 for HIV and genotype 1 for HCV.
Historical context and prevalence. HIV was discovered in
1983, as the result of an urgent hunt to account for a cluster of
deaths from rare opportunistic infections in the male gay commu-
nity that became known as Acquired Immune Deﬁciency Syn-
drome (AIDS).3 By the middle of that decade, it had become clear
that the virus had already spread throughout most of the world,
justifying the term ‘pandemic’. Since then the prevalence of HIV
infection worldwide has continued to rise, and the number of peo-
ple living with the disease has also increased inexorably from
approximately 10 M in 1990 to an estimated 34 M in 2010.4 The
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mortality due to the expansion of access to antiretroviral therapy.
In the US and Europe the impact of HIV drugs is especially appar-
ent: although the number of AIDS-related deaths has varied little
since 2000, there has been a 34% increase (to ca. 2.2 M) in the num-
ber of people living with HIV.
The high societal awareness of the disease and an unprece-
dented level of political advocacy stimulated vigorous research
into therapies for HIV in both the public sector and the pharmaceu-
tical industry, and the high level of mortality in the patient popu-
lation justiﬁed the rapid clinical advancement of exploratory
agents despite sub-optimal side effect proﬁles and treatment regi-
mens. The complications of viral resistance soon became apparent,
and the introduction in 1996 of combinations of three or more
agents (highly-active antiretroviral therapy; HAART), enabling
suppression of viral replication over many years, represented a ma-
jor milestone, with mortality, diagnoses of AIDS, and hospitaliza-
tions all falling by 60–80% in the following 3 years.5 Since then,
ever more effective and convenient drug combinations and dosing
regimens have been developed, with the impact of a once daily sin-
gle tablet regimen (STR) in 2006 particularly evident.6–8
Like HIV, it became apparent after the discovery of HCV in
19899 that the virus was widespread: a staggering 3% of the world
population has been estimated to be infected.10 Immediate public
awareness of the disease was much less than for HIV, but the long
latency of chronic infection and the huge numbers involved have
generated a substantial public health threat. Infection with HCV
has become the leading cause of liver transplantation in the
US;11 a marked increase in HCV-related hepatocellular carcinoma
is evident,12 and mortality due to the sequellae of chronic HCV
infection overtook HIV in 2007.13
Infection through blood transfusions prior to routine screening
for HCV contributed to the widespread prevalence for the virus.
Currently, both HIV and HCV are transmitted predominantly
through the sharing of contaminated needles by intravenous drug
users or through unprotected sex, particularly where there is a risk
of compromising the mucosal barrier.14
HIV and HCV viral replication cycles and the clinical conse-
quences of chronic infection. HIV is a retrovirus, transmitted as
single-stranded, positive-sense RNA. Following entry into T lym-
phocytes, the viral RNA genome is reverse-transcribed into dou-
ble-stranded DNA by the enzyme reverse transcriptase. The viral
DNA is then transported to the nucleus and permanently inserted
into the host genome through the action of viral integrase. Subse-
quent viral genome expression generates new viral RNA and pro-
teins that are packaged for release from the cell and viral
propagation. However, a prolonged period of latency (lasting many
years in memory T cells) occurs in patients with therapeutically
suppressed virus replication, making it impossible with current ap-
proaches to achieve total viral eradication in patients and mandat-
ing life-long therapy to prevent disease progression. Suppression of
viral replication without pharmacological intervention is extre-
mely rare, with the few known ‘elite controllers’ being the subject
of intense scientiﬁc interest. The normal (untreated) consequence
of acute infection with HIV is a 5–7 year period of clinical latency,
followed by a gradual rise in viral load in plasma, a reduction in
CD4+ T lymphocyte count, constitutional symptoms and opportu-
nistic diseases, resulting in death, usually within a decade after
the primary infection.15
Following the cloning of HCV, elucidation of its biology was ra-
pid and undoubtedly beneﬁtted from prior experience with HIV.
HCV is also transmitted as single-stranded, positive-sense RNA;
RNA replication takes place in the cytoplasm of host liver cells
via an assembly of viral and host proteins known as the replicase
complex. With no integration into the host genome, complete
eradication of the virus is possible. Unlike HIV, where the effectivehost immune response is speciﬁcally disabled by the virus, acute
infection with HCV does not always lead to long-term disease:
approximately 20% of individuals escape chronic infection. When
chronic infection is established, further disease progression is
slower than for HIV and highly variable, with ca. 10–15% individu-
als progressing to cirrhosis (and beyond, into hepatocellular carci-
noma and end-stage liver disease) over the following 20 years.16
It is estimated that the average HIV-1 generation time (the time
from release of a virion until a new viral particles are released from
a subsequently-infected cell) is 2.6 days, and that total virion pro-
duction in the average patient is 1  1010 daily.17 Typically 103–
106 virions/ml are found in plasma, with concentrations in lymph
nodes 2–3 orders of magnitude higher. For HCV, total virion pro-
duction per day is estimated to be even higher (ca. 1012), with
106–107 infectious units of RNA/ml plasma.18
In general, RNA viruses exhibit a much higher replication error
rate than their DNA counterparts, and this is evident for both HIV
and HCV: while HIV generates approximately 3  105 errors per
base per replication cycle,19 HCV generates even more (about
1  104/cycle).20 The higher viral load and error rate for HCV over
HIV allows the former to sample genetic space more efﬁciently,
with a swarm of quasispecies (of varying ﬁtness) populating indi-
vidual patients, and in general resistance emerges more rapidly
with monotherapy in HCV than HIV. HCV genetic diversity is also
much broader than that of HIV, and as a consequence targets for
HCV therapy are less conserved; whilst most HIV drugs are active
against all subgroups and clades of HIV-1 (and often also HIV-2 and
SIV), an on-going challenge for HCV is to ﬁnd agents outside the
nucleoside class that retain activity across all genotypes.
Comparisons by mechanistic class. Inhibitors of the viral poly-
merases and proteases are prominent in the clinical armamentar-
ium for both viruses, and are compared by class below. Agents
with clinical utility acting via other mechanisms unique to the
virus (integrase and CCR5 for HIV, NS5A for HCV) are then dis-
cussed as a group.
Nucleoside and nucleotide polymerase inhibitors. These drugs, re-
garded as the backbone of therapy in HIV and highly valued in HCV
due to their high barrier to resistance, inhibit viral replication
through incorporation into the nascent viral nucleic acid and sub-
sequent chain termination. As such, the bioactive entities are
nucleoside triphosphate analogs that compete with the natural
nucleotide pools within infected cells as substrates for the viral
polymerase. To generate these, nucleoside inhibitors must undergo
three kinase-mediated intracellular phosphorylation steps,
whereas nucleotide inhibitors bypass the ﬁrst step by delivering
a monophosphate analog directly into the cell. As might be ex-
pected, the medicinal chemistry of these agents is dominated by
the twin challenges of selectivity for viral over host polymerases
(affecting therapeutic index) and by the effective delivery and
half-life of the bioactive species in the target tissue (affecting dose
and regimen, respectively).
The ﬁrst antiretroviral agent to be studied clinically for the
treatment of HIV was Zidovudine (AZT; Fig. 1). The molecule ex-
isted21 before the virus was discovered, and its activity was re-
vealed in early screening efforts; it advanced very rapidly into
and through clinical trials, receiving regulatory approval (after only
3 years) in 1987. A further ﬁve nucleosides followed, including the
once-daily abacavir, before the only nucleotide, tenofovir dipivoxil,
was approved 14 years later. The most recent nucleoside to be ap-
proved was Emtricitabine (FTC), in 2003.
Analogs of each of the natural bases are represented in the fam-
ily of approved antiretroviral nucleos(t)ides. The ribose sugar can
be replaced by unsaturated, thioacetal and even acyclic alterna-
tives, illustrating the tolerance of reverse transcriptase for sub-
strate diversity, but all the agents lack a 30-OH substituent,
ensuring chain termination following incorporation. The nucleo-
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acid derivative tenofovir lacks oral bioavailability. In this case efﬁ-
cient loading of lymphatic cells is achieved through oral adminis-
tration of the bis-methyleneoxycarbonate ester (which,
interestingly, is not observed in plasma).22
The discovery of nucleosides for the treatment of HCV beneﬁt-
ted from exploratory work with bovine viral diarrhea virus as a
surrogate system prior to the availability of the replicon assay. De-
spite intensive efforts, the generation of clinically-useful agents
has taken far longer than for HIV. Ironically, the prototypical HCV
chain terminator 20-C-Me-A (in which elongation is prevented for
steric reasons), like AZT, existed before the virus was discovered,23
but ﬁnding an acceptable balance between facility for intracellular
phosphorylation, rate of incorporation, selectivity over host poly-
merases (i.e., safety), and oral bioavailability has proved a formida-
ble challenge. Furthermore, the stringency of the structural
requirements for chain incorporation for HCV is such that it has
proven impossible to identify nucleoside phosphonates, analogous
to those developed for HIV, with useful levels of activity.
Valopicitabine24 was the ﬁrst agent to demonstrate the poten-
tial value of the class, entering clinical trials 5 years after the avail-
ability of the replicon assay (15 years after the discovery of the
virus). Oral bioavailability was achieved through active transport
of the valine prodrug of the nucleoside. Clinical attrition of this
and subsequent candidates has been high. The most promising
agent in the class is sofosbuvir, which is currently in Phase 3; in
this case the ﬁrst kinase step is by-passed by direct delivery of
the monophosphate into hepatocytes through the use of a phos-
phoramidate prodrug. The long intracellular half-life of the tri-
phosphate enables once-daily dosing.25
Non-nucleoside polymerase inhibitors (NNIs). Many allosteric
inhibitors of HIV reverse transcriptase and HCV NS5B have been
discovered, all through high-throughput screening (HTS). For re-
verse transcriptase, there is a single site to which diverse struc-tures bind that is somewhat plastic and largely hydrophobic in
nature, with no ionic interactions. Thus while it proved easy to
achieve good levels of activity in vitro, incorporating sufﬁcient
metabolic stability and solubility for clinical utility was more difﬁ-
cult. Nevirapine26 (Fig. 2) was the ﬁrst HIV non-nucleoside reverse
transcriptase inhibitor (NNRTI) to be approved, in 1996 (12 years
after the availability of the cell-based assay). Four other NNRTIs
have followed, with the most recent, rilpivirine,27 approved in
2011.
In contrast to reverse transcriptase, at least four distinct alloste-
ric sites have been identiﬁed on NS5B by which the enzyme can be
inhibited. The optimization of HTS hits for all of these sites was
facilitated by protein crystallography, with the structure of
NS5B28 becoming available at about the same time as the replicon
assay. The ﬁrst HCV clinical candidate came from pioneering work
at Japan Tobacco29 and entered the clinic only 2 years after the rep-
licon became available, but it and many other agents since have
failed to progress beyond initial studies. More recently the situa-
tion has improved, and Figure 2 displays the structures of the most
advanced agents to date; all are in Phase 2b clinical trials. BMS-
79132530 binds at Thumb Site 1, lomibuvir31,32 at Thumb Site II,
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rive much of their potency from hydrophobic interactions, but
three of the four also contain an acidic residue that is critical for
activity. These compounds are therefore the result of careful mod-
ulation of plasma protein binding and minimization of both Phase
1 and Phase 2 metabolism; despite this, the low volume of distri-
bution inherent to lipophilic acids makes it difﬁcult to achieve a
once-daily proﬁle.
Protease inhibitors. The proteases of both HIV and HCV have
been the targets of intensive research efforts ever since their iden-
tiﬁcation, and in both cases rational design approaches based upon
knowledge of the substrate and the catalytic mechanism have been
the most successful. HIV is an aspartyl protease that has become
particularly well known for crystallographic studies, but it was
the similarity to another aspartyl protease, renin, which provided
the initial impetus for lead discovery; the ﬁrst HIV protease inhib-
itor to enter the clinic, saquinavir (Fig. 3),35 did so in approximately
a year after the protein crystal structure was solved.36 The struc-
tural hallmark of the series is the secondary alcohol that mimics
the hydrated amide of the transition state.
Saquinavir received regulatory approval in 1995, 11 years after
cell-based assays became available, and nine other agents followed
over the next decade. Just as for the peptide-based renin inhibitors,
achieving satisfactory plasma levels following oral administration
was non-trivial, but the ﬁeld was transformed by the ﬁnding that
ritonavir, the second agent to be approved, irreversibly inhibits
CYP 3A4 during the course of its metabolism.37 The dose required
for complete inhibition of CYP 3A4 is only 1/6 of the therapeutic
dose for inhibition of viral replication, and ritonavir is co-adminis-
tered at this lower dose with six of the eight subsequent agents to
boost their pharmacokinetics. Unfortunately, ritonavir is adminis-
tered in soft-gel capsules, adding to the pill burden for patients.
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Figure 3. Examples of pwithin the class due to its reduced potential for lipidogenesis and
its once-daily proﬁle.38
The fundamental and general medicinal principle that free (un-
bound) drug is the species that drives efﬁcacy emerged partly
through lessons learned in the clinical evaluation of HIV protease
inhibitors,39 and a unique feature of the class is that, while resis-
tance to the ﬁrst generation of PIs is readily generated in vitro, sec-
ond generation PIs such as darunavir require multiple mutations in
the active site of the enzyme to generate resistant viral progeny
whose replicative ﬁtness is often substantially attenuated.
Breakthrough of PI-resistant mutants clinically is rarely seen:
the time within the dosing interval that free drug levels are sufﬁ-
cient to inhibit the wild-type but not mutant virus is relatively
short.40
In contrast with HIV, HCV NS3 is a serine protease, and two dis-
tinct strategies for inhibitor design have been pursued. The ﬁrst to
succeed was the covalent-reversible ketoamide class, with boce-
previr41 and telaprevir42 (Fig. 3) receiving approval on successive
days in May 2011. However, the ﬁrst entrant into clinical trials
was the product-like carboxylic acid BILN-2061, the result of
extraordinarily innovative work at Boehringer Ingelheim.43 Here
dramatic potency enhancement was achieved through incorpora-
tion of a large quinoline-based moiety extending beyond the P2
position and lying over the relatively ﬂat surface of the protein.
Further medicinal innovation is evident in the proactive use of
new synthetic methodology (oleﬁn metathesis) to incorporate a
macrocycle to reinforce the bioactive conformation.
Competition in the product-based inhibitor series has been in-
tense, and three candidates have reached Phase 3 trials, with
asunaprevir44 being studied in an all-oral regimen (with daclatas-
vir, see below) in GT 1b patients.
PK–PD relationships of HCV protease inhibitors are interesting
in that, in several cases, active transport into hepatocytes appearsRitonavir
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those in plasma, leading to greater efﬁcacy than would be pre-
dicted by plasma exposure.45
In an era in which medicinal chemists have become far more
aware of molecular properties that are typical for oral drugs and
that avoid toxicological liabilities,46 NS3 protease inhibitors are
notable for the extent to which they transgress the Lipinski guide-
lines. This serves as a reminder that useful oral drugs can still be
found even when the target binding site mandates large molecules
with many H-bond donor and acceptor atoms to confer sufﬁcient
inhibitory potency.47
Agents acting via other mechanisms. Integration into the host
chromosome is an essential step in the replication cycle of HIV.
This complex process involves endo-cleavage of a dinucleotide
from the 30 end of the proviral DNA (‘30-processing’) followed by
nucleophilic attack of the newly-liberated 30-OH groups on the
phosphodiester backbone of the host DNA (strand transfer), both
steps of which are catalyzed by the viral integrase. As with many
enzymes manipulating phosphate esters, Mg2+ is an essential
cofactor for integrase, and early HTS (based upon 30-processing as-
says) identiﬁed both small molecule and natural product-derived
b-ketocarboxylates as hits. Despite optimization to excellent levels
of potency in enzyme assays, none of these series demonstrated
antiviral activity, and it was not until the advent of a strand trans-
fer assay approximately a decade after the discovery of the virus
that the situation was remedied.48 Pharmacokinetic optimization
then presented a further signiﬁcant challenge, with excellent met-
abolic stability required to mitigate low volumes of distribution
and yield an acceptable half life in vivo. Consequently it took
approximately 20 years from the availability of an antiviral assay
for the ﬁrst candidate, raltegravir,49 to enter the clinic, and ap-
proval (with a twice-daily regimen) followed in 2007. The second
agent, elvitegravir,50 was approved in 2012, and in this case a very
direct beneﬁt was derived from innovation in HIV protease inhib-
itors: the once-daily regimen is achieved through pharmacokinetic
enhancement with cobicistat (Fig. 4), which is an irreversible
inhibitor of CYP3A4, designed from ritonavir, completely lacking
HIV protease activity—thereby avoiding any risk of protease resis-
tance development in a protease-free regimen.51
Another product of a long discovery history is maraviroc, which
antagonizes the interaction of HIV with the host surface receptor
CCR5. In this case, once the biological details of entry had been
established,52 lead optimization of lipophilic amines found by
HTS required careful modulation of both logP and pKa, as well as
minimization of metabolism, to avoid hERG channel interactions
and CYP inhibition.53 As a result, the rate of advancement into
and through clinical trials was similar to that of the integrase
inhibitors. Speciﬁc details for the mechanism of entry of HCV into
hepatocytes, by contrast, remain relatively poorly deﬁned.
The discovery of daclatasvir was a tour-de-force of meticulous
phenotype screening, completely dependent upon the availability
of the HCV replicon assay.54 Following HTS, the initial relatively
weak activity of a hit was found not to be associated with the
structure of the principal molecular component in the screening
well. Bioassay-guided fractionation of the minor components of
the mixture identiﬁed a dimeric byproduct with picomolar activity
that provided the starting point from which daclatasvir was opti-
mized. While it has been established that NS5A is essential for viral
replication, its function remains unknown, and the locus of action
of daclatasvir was identiﬁed as being on NS5A by resistance stud-
ies. Initial clinical results with daclatasvir, announced in late
2008,55 were startlingly positive (3.3log10 reduction in viral RNA
in plasma following a single 100 mg dose) and stimulated immedi-
ate and intense competition. Daclatasvir has reached Phase 3, and
already several related compounds are also in advanced clinical
development. Like the NS3 protease inhibitors, these compoundsare all striking for their non-compliance with conventional struc-
tural guidelines for orally effective drugs.
Clinical combinations of antivirals and single-tablet regi-
mens. The advent of HAART, while representing a major medical
advance in the ability to suppress HIV replication over many years,
presented a real problem for patients. Initial antiviral combinations
involved diverse and complex regimens involving 20–30 tablets
and/or capsules daily,56 with differing dosing frequency and limita-
tions relative to mealtimes, diet and sleep. It has since been shown
that resistance emerges when as few as one in 20 doses are
missed,57 making long-term compliance to maintain viral suppres-
sion practically impossible. Thus the ingenuity of the medicinal
chemist in devising drugs with once-daily regimens was particu-
larly important for maximal patient beneﬁt—and further, the
reduction in dose to enable the development of STRs was an impor-
tant advance (no small task, given the doses that are typical of anti-
infectives). In practice, HAART was introduced in 1996, but it took
until 2006 for the ﬁrst once daily STR (Atripla; tenofovir dipivoxil
300 mg, emtricitabine 200 mg and efavirenz 600 mg) to be ap-
proved. A mark of how the ﬁeld has evolved with regard to combi-
nation regimens is that two of the four components in the most
recently-approved STR (elvitegravir and cobicistat in Stribild™)
had not received prior approval as single agents.
From the clinical experience with HIV, it was apparent for HCV
that combination therapy with antivirals was likely to be required
for effective viral suppression. Ironically, the initial introduction of
direct-acting antivirals has actually complicated therapy. Prior to
the introduction of the ﬁrst protease inhibitors, standard of care
constituted administration of pegylated interferon and ribavirin
for 48 weeks. Although the addition of a protease inhibitor to this
regimen improves SVR rates from 55% to 75%, the treatment
burden for the patient is substantially increased, with the side ef-
fects of telaprevir and boceprevir adding to the poorly-tolerated
earlier agents. Furthermore, both compounds require administra-
♠♠
projected projected
projected projected
projected
-10 -5 0 5 10 15 20 25 30
Year relative to availability of cell-based viral replication assay
Discovery of virus
Protein crystal structure solved
Availability of cell-based assay
Entry into Phase 1
First approval in class
Subsequent approvals
Clinical trials with combination regimens
Approval of one pill, once daily regimen
Legend
Color by virus:
HIV           
HCV
Shape by drug class:
Nucleoside
Non-nucleoside
Protease
Integrase
CCR5
NS5A
Combination
Markers are jittered
♠
Figure 5. Comparative chronology of direct-acting antiviral drug discovery for HIV and HCV.
2286 W. J. Watkins, M. C. Desai / Bioorg. Med. Chem. Lett. 23 (2013) 2281–2287tion three times a day. Thus, interferon-free (and preferably ribavi-
rin-free) regimens hold the prospect of a beneﬁt to the patient
analogous to HIV, with a once-daily single tablet regimen the ulti-
mate goal. The pioneering study of a combination of non-approved
drugs in an interferon-free regimen (the nucleoside prodrug meri-
citabine with the PI danoprevir in the INFORM-1 trial)58 therefore
represented a further important innovation in the ﬁeld.
Chronological comparisons. In comparing the rates of drug
discovery for HIV and HCV, two differences in clinical context must
be borne in mind. The race to discover agents to treat HIV infection
was driven by an urgent need for saving lives in the face of no
alternatives. For HCV, the availability of interferon-based regimens,
although of limited efﬁcacy, mandated a more stringent safety pro-
ﬁle for the ﬁrst direct-acting antiviral agents. Another important
difference is the logistics of late-stage clinical trials: whereas these
are typically of 48 weeks duration for HIV, the time to SVR for HCV
has been falling as the potency of the regimens has improved and
trials of only 12 weeks duration are now common. The larger pool
of HCV patients also facilitates enrollment.
It is evident from the normalized timeline in Figure 5 that the
rate of clinical advancement of HIV nucleosides was extraordi-
narily rapid, with ﬁrst approval almost a decade earlier than all
other classes for either virus. The NNIs show the greatest difference
in clinical timelines: although the ﬁrst HCV NNI started Phase 1
very shortly after the replicon became available, the HIV NNRTI
nevirapine reached approval at least four years faster than is likely
to be the case for HCV. The ﬁrst HCV protease inhibitor entered the
clinic at about the same time relative to the availability of a cell-
based assay as the ﬁrst HIV protease inhibitor, and the speed to
ﬁrst approval (although for a different agent) was also similar.
HCV NS5A inhibitors are the only other class whose speed of devel-
opment matches nucleosides, NNIs and PIs—perhaps as a conse-
quence of their phenotypic mode of discovery.
The impact of combination regimens in the treatment of HIV
has had a profound inﬂuence upon HCV drug discovery. Not only
did it stimulate multiple avenues of research in parallel to discover
mechanistically complementary agents, but clinicians have been
quick to adopt analogous combination strategies. This is evident
from Figure 5 in that the initiation of clinical trials with combina-
tion agents for HCV predates ﬁrst approval for any agent, whereas
for HIV the introduction of HAART came over a decade after the ap-
proval of AZT.Overall, it took 12 years for three classes of HIV agents to be
available to patients (Nucs, NNIs, PIs), with the fourth and ﬁfth
classes (CCR5 antagonists and integrase inhibitors) following
11 years later. By contrast, projecting success from current Phase
3 candidates, four classes of HCV agents will be available in
16 years from the invention of the replicon (ca. 2015), and there
are clear indications from Phase 2 studies that interferon-based
regimens will soon become obsolete. Most dramatically, it seems
reasonable to project that the ﬁrst once daily STR for the treatment
of HCV will become available at least 5 years faster than for
Atripla.
Conclusions. The AIDS virus was discovered in 1983, and it was
not until 2006 that the pharmaceutical industry delivered the max-
imum beneﬁt to patients in the form of a once-daily STR to enable
chronic compliance. HCV was discovered 6 years after HIV, and the
replicon assay became available a full 15 years after cell-based HIV
replication assays. The mechanistic similarity between the viruses,
the dramatic advances in molecular biology and biochemical sci-
ence, as well as the general improvement in ability to optimize
for and predict human pharmacokinetics in the intervening years,
might lead one to hope that the time to delivery of similarly safe,
efﬁcacious and convenient regimens for HCV patients would be
substantially shorter.
Two general recent advances in medicinal chemistry are indeed
apparent when reﬂecting on HCV drug discovery efforts so far.
Firstly, there has been widespread application of lessons of PK–
PD previously established across all therapeutic areas, but particu-
larly in infection, with the free drug principle pre-eminent. Sec-
ondly, new synthetic methodology continues to play a key
enabling role: the NS3 protease ﬁeld has been greatly inﬂuenced
by the use of oleﬁn metathesis to explore the beneﬁt of macrocy-
clic structures, and this in turn has engendered similar exploratory
efforts in other contexts.59
Despite these technological advances, the speed with which the
ﬁrst HCV agents entered the clinic was no faster than for HIV, and
the time taken for boceprevir and telaprevir to reach approval was
no faster relative to the ﬁrst HIV drugs. Why is this? Apart from the
special circumstances contributing to the urgency for HIV drugs
described above, we contend that it remains a profoundly chal-
lenging exercise to identify molecules with the properties neces-
sary for clinical utility, illustrating the need for long-term
commitment to ensure success. It is notable that none of the com-
W. J. Watkins, M. C. Desai / Bioorg. Med. Chem. Lett. 23 (2013) 2281–2287 2287ponents of marketed STRs for HIV were ﬁrst-in-class for their mode
of action; rather, the paradigm was one of learning from the clini-
cal shortcomings of early compounds to inform the design of sub-
sequent drugs. The same paradigm is being applied in HCV, but in
this case once-daily compounds suitable for convenient regimens
are emerging considerably more rapidly.
The discovery of drugs for the effective treatment of chronic HIV
infection has been a dramatic success for medicinal chemistry, and
we are on the verge of realizing a second major achievement in
addressing the challenge posed by HCV. Although the initial rates
of discovery have not differed dramatically, there is every reason
to expect from the diverse agents currently in late-stage clinical
trials for HCV that the ultimate once-daily STR regimen will indeed
become available much more rapidly than for HIV, transforming
the lives of patients and, through reducing the morbidity associ-
ated with end-stage liver disease, providing a substantial beneﬁt
to society in general.
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